While long-term weight-loss maintenance is addressed in detail in Chapter 9, foundational behavioral components such as consistent self-monitoring, stable eating routines, and stimulus control are already associated with reduced relapse risk in observational and interventional data [93, 94]
Genetic Modulation: Analysis of the peptides capacity to shift the expression of aging-related genes toward a more youthful state
The American Diabetes Association (ADA) guidelines recommend specific GLP-1 agonists with proven cardiovascular benefit (such as liraglutide, injectable semaglutide, and dulaglutide) for patients with type 2 diabetes and established atherosclerotic cardiovascular disease
With continued medication use, spontaneous resolution has been documented at four to six weeks and up to four months
Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk
Cell cycle regulation: p53-p21-RB signaling